Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Acumen Pharmaceuticals(ABOS) Newsfilter·2025-03-19 20:00Acumen Pharmaceuticals(ABOS) Newsfilter·2025-03-19 20:00
R1Acumen Pharmaceuticals(ABOS) Newsfilter·2025-03-19 20:00